Last reviewed · How we verify
NCT05655026: NIRA
NIV-FOB, HFNC-FOB- Comparison of Methods
NA trial testing NIV, HFNO in Respiratory Failure in 300 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Medical University of Silesia |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 300 |
| Start date | 1 January 2023 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- NIV, HFNO
Conditions studied
- Respiratory Failure — all drugs for Respiratory Failure →
- Hypoxemia — all drugs for Hypoxemia →
- Hypoxemic Respiratory Failure — all drugs for Hypoxemic Respiratory Failure →
Sponsor
Medical University of Silesia
Who can join
18 and older, any sex, with Respiratory Failure or Hypoxemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to asses safety and indications and contraindications for performing bronchofiberocopy (FB) with respiratory support methods, i.e. non-invasive ventilation (NIV) and high flow nasal oxygen therapy (HFNO). Additionally, researchers want to determine how using these methods could avoid the risk of most common complications such as: hypoxemia-related events, decompensation of chronic respiratory failure, worsening of gas exchange, hemodynamic instability.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05655026
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Failure
Currently open trials in the same condition.
- NCT07522450 — Benefit of Sleep Quality Monitoring by EEG in ICU · recruiting
- NCT07359261 — Transpulmonary Assessment for Individualized Lung Optimization in Obese Patients · Phase 2 · recruiting
- NCT07536750 — Comparison of the Efficacy and Safety of Ciprofol Versus Propofol for Sedation in ICU Patients Undergoing Non-Invasive V · recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
- NCT06591533 — The Effect of Music Therapy on Vital Signs and Heart Rate Variability of Pediatric Patients During the Extubation Proces · NA · recruiting
Other Medical University of Silesia trials
Trials by the same sponsor.
- NCT06212674 — Single-stage Pulmonary Vein Isolation Combined With Percutaneous Left Atrial Appendage Occluder Implantation in Patients · Phase 4 · recruiting
- NCT06970002 — Respiratory Stabilization in Chronic Acidosis Before Bronchofiberoscopy & Non-Invasive Ventilation Effectivenes · NA · not yet recruiting
- NCT07137299 — POPQ Associated With Total Laparoscopic Hysterectomy · not yet recruiting
- NCT06970041 — To Assess the Types of Mechanical Ventilation in Enabling Therapeutic Bronchofiberoscopy in Patients With Decompensated · NA · not yet recruiting
- NCT07120529 — Minimally Invasive Surgery Versus Open Radical Hysterectomy in Presumably Early Stage Cervical Cancer: a Retrospective M · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05655026 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Silesia
- Last refreshed: 16 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05655026.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing